Home › Lymphoma › Pennsylvania
Lymphoma clinical trials in Pennsylvania
24 studies for Lymphoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- The Children's Hospital of Philadelphia (CHOP), Philadelphia
RecruitingPhase 1
24 Months – 18 Years · All sexes · Updated Sep 25, 2026 · NCT06441331A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07015242A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500Collection of Tissue Samples for Cancer Research
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Philadelphia
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 14, 2026 · NCT06137144CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Thomas Jefferson University, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06624085Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Pittsburgh
RecruitingPhase 3
Ages 18 to 18 · All sexes · Updated Sep 8, 2026 · NCT07509151TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- Hospital of the University of Pennsylvania, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07082803Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Lehigh Valley Topper Cancer Center Institute, Allentown
- Thomas Jefferson University, Philadelphia
- West Penn Hospital, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07192471A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Allegheny Health Network, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Allegheny Health Network Cancer Institute, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1
Ages 0 to 29 · All sexes · Updated Jul 7, 2026 · NCT06934382A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site 2, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Jun 4, 2026 · NCT06131801Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Saint Christopher's Hospital for Children, Philadelphia
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- UPMC Hilman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- Community Medical Center, Scranton
- and 1 more
RecruitingPhase 3Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Jan 13, 2026 · NCT05006482CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
- University of Pennsylvania - Abramson Caner Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2025 · NCT06420089Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2025 · NCT04234048From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.